Boston Scientific Drops $1.5B on Game-Changing Nickel-Free Heart Valve Tech + $2B Buyback
Boston Scientific invests $1.5B in MiRus for new heart valve tech and launches $2B buyback to boost shares and growth.
/ 1655 items
#XY↓
Relay Therapeutics’ Zovegalisib Delivers Strong Early Results in Rare Blood Vessel Disorder
Relay Therapeutics’ drug zovegalisib showed strong results in shrinking rare blood vessel disease lesions with good safety.
DT-216P2 Shows Rapid Improvement in Friedreich Ataxia After Just 4 Weeks
Design Therapeutics’ DT-216P2 improved Friedreich ataxia symptoms in early trial, increased frataxin levels and was well tolerated with no serious side effects.
Regeneron’s Melanoma Drug Crumbles Against Keytruda in Phase 3 Trial
Regeneron’s fianlimab + Libtayo combo showed 11.5 months PFS vs Keytruda’s 6.4 months in Phase 3 melanoma trial — but missed statistical significance. Analysts are “shaking heads” after the setback.
Elliott Takes Aim at Bio-Rad: Activist Investor Pushes for Turnaround
Elliott bought into Bio-Rad to boost its weak stock, betting on turnaround and its valuable Sartorius stake driving future growth.
Wall Street Upgrades Two Biotech Stocks: STRO Price Target Tripled, ORIC Now a Buy
Wedbush lifts Sutro to $60 on STRO-004 hopes; ORIC upgraded on strong cancer data and big market potential.